A complete surgical resection is the most important objective of cancer surgery. Yet the methods currently used to identify malignant tissue are limited – skilled surgeons often rely only on preoperative imaging and real time visual and tactile cues.
There is an unmet need for greater certainty when assessing the location and full extent of cancerous tissue while operating.
We’re developing technology where it’s needed most.
Lung, ovarian, prostate, and colorectal cancers alone make up nearly 72% of inpatient oncology procedures in the US1. On Target is developing intraoperative targeted fluorescent markers in multiple cancer types. The potential of this technology solidifies our commitment to our mission of making cancer visible during surgery so it can be removed more completely.
1. Orosco, Ryan, et al. Positive Surgical Margins in the 10 Most Common Solid Cancers. Nature. 2018; 8:5686. doi:10.1038/s41598-018-23403-5
Clinical trials are underway in more than a dozen centers to evaluate On Target Laboratories’ portfolio.
This study is designed to evaluate the efficacy of pafolacianine sodium injection (OTL38) in combination with near-infrared fluorescence imaging to detect additional ovarian cancer lesions not detected by palpation and visualization under normal light during surgeryLearn More
This study aims to assess the efficacy, safety, and tolerability of pafolacianine sodium injection and near-infrared fluorescence imaging at identifying pulmonary nodules within the operating theaterLearn More
This study is to assess the safety, tolerability and pharmacokinetics of OTL78, a PSMA-targeted fluorescent marker, for the intraoperative imaging of prostate cancerLearn more